Dossier assessment
Dulaglutide (type 2 diabetes in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dulaglutide (type 2 diabetes in children and adolescents) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dulaglutide (type 2 diabetes in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Children and adolescents aged 10 to 17 years with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
Insulin-naive children aged 10 to 17 years with type 2 diabetes mellitus who have not achieved sufficient glycaemic control with their ongoing drug treatment consisting of at least one blood-glucose lowering drug in addition to diet and exercise: added benefit not proven
Insulin-experienced children aged 10 to 17 years with type 2 diabetes mellitus who have not achieved sufficient glycaemic control with their ongoing insulin regimen in addition to diet and exercise: added benefit not proven
Project details
- Project no.
- A23-28
- Commission
- Commission awarded on 31.03.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Dulaglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Dulaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed